Lancet 2019 Apr 11
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.
Abstract
Background
The oligometastatic paradigm suggests that some patients with a limited number of metastases might be cured if all lesions are eradicated. Evidence from randomised controlled trials to support this paradigm is scarce. We aimed to assess the effect of stereotactic ablative radiotherapy (SABR) on survival, oncological outcomes, toxicity, and quality of life in patients with a controlled primary tumour and one to five oligometastatic lesions.
Methods
This randomised, open-label phase 2 study was done at 10 hospitals in Canada, the Netherlands, Scotland, and Australia. Patients aged 18 or older with a controlled primary tumour and one to five metastatic lesions, Eastern Cooperative Oncology Group score of 0-1, and a life expectancy of at least 6 months were eligible. After stratifying by the number of metastases (1-3 vs 4-5), we randomly assigned patients (1:2) to receive either palliative standard of care treatments alone (control group), or standard of care plus SABR to all metastatic lesions (SABR group), using a computer-generated randomisation list with permuted blocks of nine. Neither patients nor physicians were masked to treatment allocation. The primary endpoint was overall survival. We used a randomised phase 2 screening design with a two-sided α of 0·20 (wherein p<0·20 designates a positive trial). All analyses were intention to treat. This study is registered with ClinicalTrials.gov, number NCT01446744.
Findings
99 patients were randomised between Feb 10, 2012, and Aug 30, 2016. Of 99 patients, 33 (33%) were assigned to the control group and 66 (67%) to the SABR group. Two (3%) patients in the SABR group did not receive allocated treatment and withdrew from the trial; two (6%) patients in the control group also withdrew from the trial. Median follow-up was 25 months (IQR 19-54) in the control group versus 26 months (23-37) in the SABR group. Median overall survival was 28 months (95% CI 19-33) in the control group versus 41 months (26-not reached) in the SABR group (hazard ratio 0·57, 95% CI 0·30-1·10; p=0·090). Adverse events of grade 2 or worse occurred in three (9%) of 33 controls and 19 (29%) of 66 patients in the SABR group (p=0·026), an absolute increase of 20% (95% CI 5-34). Treatment-related deaths occurred in three (4·5%) of 66 patients after SABR, compared with none in the control group.
Interpretation
SABR was associated with an improvement in overall survival, meeting the primary endpoint of this trial, but three (4·5%) of 66 patients in the SABR group had treatment-related death. Phase 3 trials are needed to conclusively show an overall survival benefit, and to determine the maximum number of metastatic lesions wherein SABR provides a benefit.
Funding
Ontario Institute for Cancer Research and London Regional Cancer Program Catalyst Grant.
Related Questions
How would you treat a newly diagnosed hormone sensitive high risk prostate cancer with one small lung metastasis and no other evidence of metastatic disease per PSMA PET?
I think there is no solid answer to this. De-novo visceral metastases are very rare in mHSPC, and lung-only oligometastases on PSMA-PET are even more rare. Since lung metastases is expected to be visible on CT, this is undeniably a high-volume disease based on the CHAARTED criteria. Patients with vi...
Would you offer whole lung radiation therapy in a head neck patient who relapsed with multiple lung only mets?
I would definitely not do WLI in this scenario, refer to Med Onc for systemic therapy. Makes perfect sense to consider SBRT or limited resection if there's only limited biopsy proven disease or a persistent lesion despite systemic therapy, as stated in the much more eloquent and detailed answer abov...
How do you approach a prostate cancer patient with oligomet disease on PSMA PET?
I think there is a spectrum of 'PSMA-PET Avid lesion suspicious for metastasis'. In some locations, such as ribs, I worry more about false positives. For lesions with PET avidity without CT correlate, I worry about false positives and may advocate for a biopsy if it will change the treatment plan. S...
What is the general approach for HPV+ OPSCC who present with distant metastases?
It depends in part on the extent of the distant disease. In a true oligometastatic with one or two lesions, I would still take a curative approach with the appropriate management of the metastatic site. We would likely have a discussion on whether it is M1 to start with induction therapy, but I thin...
Would you treat the prostate alone, or prostate and mets in an oligometastatic prostate cancer patient?
It's a good question and we are tempted to answer "prostate and mets" as the literature is building up, but we are still waiting for randomized phase III trials. The evidence so far suggests that stereotactic ablative radiotherapy (SABR) is promising. SABR-COMET trial has shown an improved OS for SA...
Do you ever prophylactically treat an asymptomatic bone metastasis to prevent or delay risk of pathologic fracture?
Yes, this is a situation I have encountered before and I think it is very reasonable to deliver prophylactic RT if there is cortical thinning indicating fracture risk, or if there is documented growth of the metastatic lesion, even in the absence of any symptoms to palliate. Another situation in wh...
What duration of ADT do you recommend for a patient with locally treated prostate cancer who undergoes metastasis-directed radiation therapy to a single oligometastatic bone lesion?
While I agree with @Dr. First Last that very small studies like STOMP and ORIOLE suggest that a small subset of men can delay the need for ADT by 1-3 years, this is not level 1 evidence. Most men with oligometastatic HSPC will still progress with metastasis directed therapy alone over a short time h...
Are you considering SBRT in your prostate cancer patients who had a RP and now have a rising PSA and oligometastatic bone disease?
Yes, we offer SBRT for oligometastatic disease, with a frank discussion of current understanding of the potential benefits and risks. We await results of phase III trials, but smaller trials have been encouraging for a progression-free survival benefit (SABR-COMET, STOMP, ORIOLE).
What adjuvant therapy would you offer a fully resected isolated pelvic peritoneal recurrence of a uterine serous carcinoma?
Although the recurrence appears to be isolated, peritoneal recurrence of serous endometrial carcinoma suggests more than localized disease, thus systemic therapy is appropriate. Because the most common site of another recurrence is in the vicinity of the resected metastasis, stereotactic local radia...
What is the best SBRT dose-fractionation scheme for oligometastatic disease in the adrenal gland?
I don't think we have established a true "best" SBRT dose-fractionation schedule for any anatomical site, even the common ones where we have randomized trials comparing different dose regimens (ie lung), as the volume of data provides successful and acceptable alternatives but not necessarily a defi...
What SABR dose-fractionation would you use when treating an oligometastatic site in the femur or weight-bearing acetabulum?
This is a very good question. We only excluded femoral sites from COMET out of an abundance of caution, not because of any evidence suggesting fractures in this location.We were worried that a couple of fractures would not only cause harm, but would also end the trial, particularly as they can lead ...
Would you offer PA nodal XRT in a patient with rising PSA and multiple PET positive nodes after previous prostate XRT treatment that is otherwise locally controlled?
This is a great question, and one that is being explored more and more, particularly for young, healthy patients with well-controlled primary disease. In addition, we are seeing more of these patients due to novel developments in imaging that can detect disease at much lower PSA values than before (...
Do you consider initiating systemic therapy for patients with NSCLC who develop oligometastatic disease and have all known sites of disease treated with SBRT?
This is a very intriguing and challenging question and addresses a not so uncommon clinical scenario when patients present with one or just a few sites of recurrent disease after delivery of what was considered to be definitive therapy. In such contexts many times it appears appealing and appropriat...
Should special precautions be taken when treating oligometastatic disease in the sacrum or pelvis with SBRT in a patient with a long life expectancy?
There's so much good data now that if you can work it out (insurance, etc) it's worth doing. My suggestion is to do it, but paint within the lines, meaning don't use a dose that's poorly studied and 1) adhere to good quality dose constraints like TG101, and 2) consider the PTV coverage...in that ord...